Apollo HealthCo to market life, health insurance as corporate agent
A pilot project was successfully completed and the plan is to launch insurance products from as many as 12 insurers within the next two months. For now, it has tied up with four standalone health and four life insurers. All the insurance plans will be bundled with exclusive Apollo benefits with a focus on distributing OPD coverage in future. The company is eyeing marketing of 1 lakh policies and ₹80-100 crore in revenue in the current financial year from the insurance operations, for which it has set up a subsidiary firm, Apollo HealthCo CEO Madhivanan Balakrishnan said on Wednesday (May 14, 2025).
Sensing a growth opportunity by offering additional services to customers of the Apollo 24|7 digital healthcare platform that it operates alongside the retail network of over 6,500 stores Apollo Pharmacy, the company has decided to launch a co-branded credit card to simplify payments and reduce healthcare costs for its customers.
Conceived in collaboration with one of India's leading credit card issuers, the card will offer exclusive benefits from medicines and diagnostics to doctor consultations and wellness services. The card is expected to be launched within the next fortnight, Mr. Balakrishnan told media here.
Health Challenge
He said Apollo HealthCo is also rolling out 'Ultimate Health Programme', a first-of-its-kind preventive health initiative on the Apollo 24|7 platform. Under the programme, customers who undergo a preventive health check and receive a 100% positive report will be refunded the full value of their health package. 'Prevention is the first step to true healthcare. The health challenge is our way of encouraging every individual to prioritise early detection and wellness,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
10 hours ago
- Time of India
Mis-selling of life cover not at alarming levels: Irdai
MUMBAI: The Insurance Regulatory and Development Authority of India (Irdai) has said that mis-selling in the life insurance sector is not at alarming levels, citing grievance data published in its annual report. Speaking at an industry event, Irdai member (Life) Swaminathan S Iyer said the number of mis-selling complaints are not alarming. They currently stand at around 0.41 per 100 policies. While it is not alarming, the regulator has consistently told the industry that the number must keep going down. Insurance CEOs at the event on launch of insurance awareness campaign said that addressing mis-selling is a collective industry responsibility, and both the regulator and insurers remain committed to further reducing the number of complaints. On the issue of public listings, Iyer clarified that Irdai does not mandate IPOs but encourages insurers to consider it as they grow. There have been deep conversations between the regulator and insurers, he said. As companies mature, listing becomes a natural next step, to show the world we are strong and well-governed, he added. With policy volumes stagnating and premium growth tapering, the industry has launched a major awareness campaign titled " Sabse Pehle Life Insurance ", backed by a Rs 450 crore investment over the next three years.
Mint
18 hours ago
- Mint
Apollo Hospitals: Simplifying corporate structure could lead to rerating
Apollo Hospitals Enterprise Ltd has decided to give its existing shareholders direct ownership of its subsidiary, Apollo Healthco Ltd. Apollo Healthco will have online, offline, retail, and wholesale pharmacy segments under one umbrella, apart from the digital consultation and treatment business of Apollo 24|7. The new entity will have nearly 667 million equity shares with a face value of ₹2 each. Apollo Hospitals' shareholders will receive 195.2 shares of Apollo Healthco for every 100 shares they hold. Apollo Healthco's listing is likely in 18-21 months. The exercise would mean that Apollo Hospitals would only have a 17.5% stake (direct plus indirect through its other subsidiaries) in Apollo Healthco, as against the earlier plan of having a 59.2% stake. Also Read: Will Torrent Pharma's big bet on JB Chemicals pay off? The two separate listed entities with dedicated leadership will allow the management teams to sharpen their focus on hospital and pharmacy businesses separately. Following the announcement, Apollo Hospitals shares touched a new 52-week high of ₹7,584.50 apiece on Tuesday. Growth potential Is there more steam left based on the separate valuation of the two businesses? Well, the answer depends on the management's ability to achieve the aspirational targets for its pharmacy business—Apollo Healthco. According to the company's presentation, Apollo Healthco's FY25 revenue (pro forma without the restructuring) was ₹16,377 crore. The management aspires for an operating revenue of ₹25,000 crore in FY27, which would mean a compound annual growth rate of 24% over the two years from FY25. This would require a significant pick-up in growth, given that the FY25 revenue had increased 19% year-on-year. Excluding Apollo 24|7 losses, the FY25 Ebitda margin was already about 6%. So, the Ebitda margin target of 7% in FY27 with operational efficiencies is achievable as it would only require Apollo 24|7 to achieve breakeven. If management is able to deliver on the aspirational numbers, it would mean an Ebitda of ₹1,750 crore in FY27. Based on the EV/ Ebitda multiple of 30x assigned by analysts at Nomura, the market capitalization attributable to Healthco is about ₹50,000 crore, as the net debt is small. Ebitda stands for earnings before interest, taxes, depreciation, and amortization. Also Read: Tech Mahindra: What can upset its apple cart Apollo Hospitals' market capitalization is now ₹1.08 trillion. So, the residual market capitalization of Apollo Hospitals, after deducting the valuation of Apollo Healthco is at ₹58,000 crore. With a net debt of around ₹5,000 crore, the implied EV/Ebitda valuation multiple of Apollo Hospitals comes to 20x based on Nomura's estimate of ₹3,150 crore Ebitda for FY26 (Apollo Health and Lifestyle having sugar clinic, dental clinic, etc. not considered due to its small size). Nomura's fair value multiple for Apollo Hospitals at 25x is higher than the derived implied multiple at 20x, implying room for upside. The growth prospects of standalone Apollo Hospitals are strong. Its future growth is likely to be largely led by capacity additions, unlike the last three years to FY25, when it relied on average revenue per occupied bed (Arpob) for growth. Apollo Hospitals had 8,025 operating beds at FY25 end. This is likely to rise by more than 50% as it plans to add nearly 4,400 beds over the next 3-4 years to address supply-side constraints, even though getting more patients is also crucial. The management expects to maintain the Ebitda margin of the hospital business at 24% even after the large expansion. Also Read: Nykaa's premium bet: A smart strategy if it delivers The hospital business has a higher Ebitda margin but is more capital-intensive in nature, whereas the pharmacy business has a lower Ebitda margin but lower capital requirements. Besides, the separate listing of Apollo Healthco would mean that the shareholders of Apollo Hospitals would have an option to choose the business they want to remain invested in.
Time of India
a day ago
- Time of India
Healthcare Momentum Builds: Apollo Hospitals Poised for 2–4 Month Rally
'We are witnessing noticeable traction in the healthcare space, and Apollo Hospitals is moving in line with this trend. Traders can buy for a target of Rs 8000 in the next 2-4 months,' Ajit Mishra – SVP, Research, Religare Broking Ltd, said. Show more Show less
